Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Ungar H., Sullman S
The Denmark-based company announced Wednesday it had received a Complete Response Letter for dasiglucagon, which it was proposing for the ultra-rare genetic disease congenital hyperinsulinism, due to the timing of a third-party manufacturing facility reinspection. In an initial visit, the FDA had flagged deficiencies in a third-party contract manufacturer, which the company claims had been resolved by the time of a reinspection in August/September 2024
Inulin-type fructans and bone health: state of the art and perspectives in the management of osteoporosis
People with late complications of type 1 diabetes As there is no evidence that intensive glycaemic management slows the progression of late microvascular complications of diabetes, glycaemic targets in individuals with advanced complications should be individualised and based on the balance of risks and benefits [39, 275]
US$ 20.47
US$ 29.78
US$ 22.27
US$ 24.39
US$ 28.85
US$ 29.31
US$ 21.49
